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Atacicept, a soluble recombinant fusion protein of the human
immunoglobulin (Ig) G1 Fc and the extracellular domain of the
human transmembrane activator and calcium modulator and
cyclophylin ligand interactor receptor, acts as an antagonist of
both B lymphocyte stimulator and a proliferating–inducing
ligand. Here we determined the nonclinical safety, pharmacoki-
netics and pharmacodynamics of atacicept in mice and cynomol-
gus monkeys. Subcutaneous atacicept treatment (twice weekly in
cynomolgus monkeys, three times weekly in mice) was generally
safe and well tolerated safe and well tolerated with dosing up to 10
mg/kg every other day for up to 39 weeks or up to 80 mg/kg when
dosed for 4 weeks. At a dose of 1 mg/kg subcutaneous (sc)
bioavailability of atacicept in mice and monkeys was 76 and 92%,
with a mean serum t1/2 of 44 and 179 h, respectively. In accord
with its anticipated mechanism of action, repeated administration
of atacicept decreased serum IgG concentrations up to 50%, IgM
concentrations >99%, and circulating mature B-cell concentra-
tions up to 60%. These effects were dose-related but reversible, as
determined in a 25-week follow-up period. Microscopically, B cells
numbers were reduced in the follicular marginal zone of the spleen
and the mantle surrounding germinal centers of the lymph nodes.
These data confirm the preclinical safety and the pharmacological
activity of atacicept and support its clinical development.
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B lymphocyte stimulator (BLyS, CD257) and a proliferating–
inducing ligand (APRIL, CD256) are members of the tumor
necrosis factor ligand superfamily that demonstrate specific
activity toward B cells, and support B-cell proliferation,
differentiation, and survival (Dillon et al., 2006; Mackay et
al., 2007; Moore et al., 1999). BLyS transgenic mice harbor
increased B220þ B cells and plasma cells in the spleen and
lymph nodes, and develop antidouble-stranded DNA anti-
bodies, proteinuria, and glomerulonephritis consistent with
a systemic lupus erythematosus (SLE)–like autoimmunity as
they age (Gross et al., 2000; Khare et al., 2000; Mackay et al.,
1999). APRIL transgenic mice have a slightly increased
number of B cells in peripheral lymph nodes and increased
serum immunoglobulin M (IgM) levels (Stein et al., 2002). In
contrast, BLyS knockout mice have a markedly reduced mature
B-cell population and decreased serum Ig levels (Gross et al.,
2001), whereas APRIL knockout mice have normal B-cell
development (Varfolomeev et al., 2004) and an impaired IgA
class switching (Castigli et al., 2004). Elevated BLyS and
APRIL levels have been measured in sera from patients with
SLE (Koyama et al., 2005; Stohl, 2004) and multiple myeloma
(Moreaux et al., 2004; Novak et al., 2004), and in sera and
synovial fluid of patients with rheumatoid arthritis (Cheema et
al., 2001; Nagatani et al., 2007; Tan et al., 2003). The biologic
effects of BLyS and APRIL suggest that specific inhibitors
could have therapeutic use in the treatment of autoimmunity
and B-cell malignancies, and current clinical trials are
evaluating effects in rheumatoid arthritis, SLE, multiple
sclerosis, multiple myeloma, and non-Hodgkin’s lymphoma.
BLyS and APRIL are produced by a variety of cell types,
including cells of the myeloid lineage such as dendritic cells
and macrophages, and their expression is upregulated by
interferon-c and other cytokines (Litinskiy et al., 2002;
Nardelli et al., 2001). These ligands signal through two
common receptors: B-cell maturation antigen and transmem-
brane activator and CAML interactor (TACI) (Mackay et al.,
2003). In addition, BLyS also binds a third receptor, B-cell
activation factor of the TNF family (BAFF) receptor (BAFF-R,
also known as BLyS receptor 3, BR3). Binding of BLyS to the
majority of B cells occurs predominantly through TACI and
BAFF-R (Novak et al., 2004; Stohl, 2004). BLyS signal
transduction occurs through nuclear factor-kappa B and JNK,
and results in increased Bcl-2 and BclXL protein expression, thus
attenuating apoptosis and increasing cell survival (Amanna et al.,
2003; Baker, 2004; Mackay et al., 2003).
Atacicept has been engineered as a recombinant fusion
protein containing the extracellular, ligand-binding portion of
the human TACI receptor (with specificity for both APRIL and
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BLyS) and a modified Fc portion of human IgG1. Atacicept has
demonstrated efficacy in a variety of murine models of
autoimmunity, including a NZBW F1 murine model of
spontaneous SLE (Gross et al., 2000) and a murine model of
collagen-induced arthritis (Gross et al., 2001). To support
subsequent clinical evaluation of atacicept in autoimmunity
and B-cell malignancies, the nonclinical safety, pharmacoki-
netics (PK), and pharmacodynamics (PD) of atacicept were
evaluated and the results are summarized herein. These studies
encompassed evaluation of acute and chronic toxicity, safety
pharmacology, PK, and PD. The nonclinical studies for this
program were conducted in mice and cynomolgus monkeys
based on evidence of therapeutic activity in mouse models of
autoimmunity, demonstrable biological activity on B cells and
circulating immunoglobulin consistent with the expected
biological activity of BLyS/APRIL inhibition, and demon-
strated drug-ligand binding to BLyS and APRIL in both of
these species.
MATERIALS AND METHODS
Test Items and Formulation
All test materials were provided by Merck Serono International S.A.
(Geneva, Switzerland). The manufacturing and characterization of atacicept
have been previously described (Roque et al., 2006). Frozen aliquots of
atacicept stock solution were thawed on each day of dosing and used for dose
preparation. Atacicept stock was either used as provided for the 5.0 mg/kg dose
or diluted in phosphate-buffered solution (PBS) as needed for dosing. Stability
and recovery of the low-concentration solutions were evaluated to confirm
appropriate dosing.
Animal Care and Use and Regulatory Compliance
Toxicology studies were conducted in Swiss mice (safety pharmacology;
Depre Breeding Centre, France), in CD-1 (ICR) BR mice (general toxicology
studies; Charles River Laboratories, Italy) and with experimentally naı¨ve,
purpose-bred, young adult to adult male and female cynomolgus monkeys
(Macaca fascicularis) originating from China (general toxicology studies) or
Mauritius (safety pharmacology). All study procedures were conducted
according to a written study protocol and facility standard operating
procedures, and in strict compliance with accepted animal welfare standards.
Housing and protection of animals used in the studies were maintained in
accordance with Directive 86/609/EEC and the Italian D.L. No. 116 of January
27, 1992. All studies were conducted in accordance with the Organization for
Economic Co-operation and Development (C[97] 186 [Final]) Principles of
Good Laboratory Practice, as incorporated into EEC Directives 87/18, 88/320,
1999/11, and 1999/12, and enforced by the Italian Health Authority. The
nonclinical safety program was conducted in accordance with regulatory
recommendations for the nonclinical safety evaluation of biotechnology-
derived therapeutics (International Conference on Harmonization, 1998).
Safety Pharmacology
Evaluation of effects on respiration in unrestrained conscious mice.
Respiration was monitored in mice (eight males per group) treated with a single
dose of vehicle control (phosphate-buffered saline, PBS), positive control
(carbamylcholine, 1 mg/kg), or atacicept (5, 20, and 80 mg/kg) by sc
interscapular injection through previously implanted catheters (see Table 1).
The mice were placed in a whole body plethysmograph for measurement of
respiratory rate, peak inspiratory and expiratory flows, inspiration and
expiration times, minute volume, tidal volume, and airway resistance (Chand
et al., 1993), and respiration cycles were acquired (Dataquest A.R.T. v. 2.1,
Data Sciences, Inc., St Paul, MN) before administration of the test item and at
1, 5, 10, 15, 30, 60, 90, 120, 180, and 240 min following administration.
Behavioral Irwin test and effect on body temperature in mice. Effects on
behavior and body temperature were measured in mice (eight males per group)
following a single dose of vehicle control (PBS), positive control (chlorprom-
azine, 10 mg/kg), or atacicept (5, 20, and 80 mg/kg) by sc interscapular
injection (see Table 1). The mice were observed according to a standardized
observation battery to detect neurobehavioral, neurovegetative, or psychotropic
signs or neurotoxic effects (Irwin, 1968). Body temperature was measured via
rectal probe (Physitemp Model Ret-2, Type 2, Physitemp Instruments, Inc.,
Clifton, NJ). The Irwin scores and measurements of body temperature were
performed before administration of the test item and at 1, 3, 6, 8, 24, and 48 h
following administration.
TABLE 1
Nonclinical Safety Studies of Atacicept
Study type Species Route Regimen Dose (mg/kg)
Sacrifice (weeks)
Interim Terminal Recovery
General toxicology Mouse sc, iv Single dose 600, 1200 — 2 —
General toxicology Mouse sc Q2D 0, 5, 20, 80 2 4 4
General toxicology Mouse sc Q2D 0, 5, 20 — 4 4, 8, 16
General toxicology Mouse sc Q2D 0, 0.4, 2, 10 13 26 13
General toxicology Monkey sc Single dose 240 — 2 —
General toxicology Monkey sc Q3D 0, 5, 20, 80 — 4 4
General toxicology Monkey sc Q3D 0, 0.4, 2, 10 13 39 25
Cardiovascular safety pharmacologya Monkey sc Single dose 0, 20, 80 — — —
Nervous system safety pharmacology Mouse sc Single dose 0, 5, 20, 80 — — —
Respiratory safety pharmacology Mouse sc Single dose 0, 5, 20, 80 — — —
PKb Monkey sc, iv Single dose sc: 1, 5, 15; iv: 1 — — —
PK Mouse sc, iv Single dose sc: 1, 5, 15; iv: 1 — — —
Note. Q2D, every other day; Q3D, every third day.
aAnimals were retreated after a wash-out period as described in the Methods section.
bEach monkey received two doses, separated by a 2-week wash-out period.
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Evaluation of effects on blood pressure, heart rate, and electrocardio-
gram in conscious cynomolgus monkeys. Cardiovascular safety evaluations
were conducted in cynomolgus monkeys (three males and three females) fitted
with telemetric transmitters for measurement of blood pressure (mean, systolic,
and diastolic), heart rate, and electrocardiography via six leads (leads I, II, III,
aVL, aVR, aVF) in conscious unrestrained monkeys. The monkeys were
serially treated with vehicle control (PBS) and atacicept (20 and 80 mg/kg, see
Table 1). A wash-out period of 48 h between the vehicle and the 20 mg/kg dose
was followed by 1 week between the two doses of atacicept; no toxicokinetic
analyses were conducted on these animals and exposure was estimated based
on results from other studies. Telemetric measurements of blood pressure, heart
rate, and electrocardiography (lead II) started at least 24 h before administration
and were continued for 24 h (20 mg/kg atacicept) or 48 h (vehicle and 80 mg/kg
atacicept). The effects of atacicept were determined by comparison against
control monkeys (administered vehicle alone) and using the monkey’s own
basal values. The effects of atacicept and the method-control substance on the
QT interval were analyzed by a method that takes into account the QT/RR
relationship according to Fridericia’s formula (Fridericia, 1920), Van de
Water’s formula (Van de Water et al., 1989) and Bazett’s formula (Bazett,
1920).
General Toxicology, Pharmacokinetics, and Pharmacodynamics
The toxicity, PK, and PD of atacicept in mice and cynomolgus monkeys
were evaluated following both single and repeated dose administration, as
summarized in Table 1. General toxicology studies of atacicept sc injection
(510 ml/kg) in mice were conducted after a single dose, and after repeated
dosing every other day (Q2D) for 2, 4, and 26 weeks. As a general rule, three to
six animals per sex were evaluated for toxicological and PK endpoints at each
sampling interval, and animals were 6 weeks old at study initiation. General
toxicology studies of atacicept sc injection (interscapular or medial thigh, 13
ml/kg) in cynomolgus monkeys were conducted after a single dose and after
repeated dosing every third day (Q3D) for 4, 13, and 39 weeks. With the
exception of the high dose tolerability study, which was conducted with one
male and one female, toxicology and PK studies involved three to five male and
female animals per dose group and animals were generally 36 years old at
study initiation. Because B-cell recovery was incomplete after a 4-week dose-
free period in both species, subsequent studies were conducted to evaluate the
recovery kinetics of B cells after longer dose-free periods. Evaluations
conducted in these species generally included clinical signs, food consumption,
body weight, serum chemistry, hematology, urinalysis, flow cytometric
immunophenotyping of peripheral blood, serum Ig (IgG and IgM), ophthal-
mology, gross pathology, organ weights, and microscopic pathology. In
addition, serum samples were collected for evaluation of serum atacicept
concentrations and anti-atacicept antibody formation. Additional analyses
conducted only in cynomolgus monkeys included evaluation of plasma
coagulation and electrocardiography.
Clinical observations. Mortality observations were recorded twice daily,
and clinical observations of physical appearance and behavior were recorded
daily during the predose, dosing, and dose-free recovery phases of the studies.
Body weight measurements were recorded once weekly (monkeys) or twice
weekly (mice), and food consumption (estimated in monkeys) was recorded
weekly during the predose, dosing, and dose-free recovery phases of the
studies.
Electrocardiography. Electrocardiogram (ECG) tracings were recorded on
monkeys in general toxicology studies according to Bailey’s hexaxial lead
system by a three-channel electrocardiograph (Bosch EKG 506 D). Heart rate,
PQ interval, QRS complex, and QT interval lengths were determined from DII
tracings; QTc was calculated according to Bazett’s formula. For the recordings,
the monkeys were lightly anesthetized with 8 mg/kg Zoletil 100 (Virbac,
Carros, France; tiletamine and zolazepam 1:1) administered by intramuscular
injection. During the ECG recordings, the monkeys were kept in right lateral
recumbency. ECG tracings were recorded at various time points before dosing,
during dosing, and at the end of the treatment and recovery periods.
Ophthalmology. Ophthalmologic examinations were performed in mice or
monkeys by macroscopic examination of the conjunctiva, cornea, anterior
chamber, iris, lens, vitreous body, and fundus by means of an indirect
ophthalmoscope (Omega 100, Heine Optotechnik, Herrsching, Germany) after
instillation of 0.5% tropicamide (Visumidriatic fenilefrina, Visufarma, Italy) in
both eyes. Ophthalmology examinations were conducted during the predose,
dosing, and recovery phases of the studies.
Clinical pathology. Blood and urine samples were collected periodically
for clinical pathology analyses during the predose (cynomolgus monkeys) and
postdose (mice and cynomolgus monkeys) periods. For example, for the
chronic toxicity study in cynomolgus monkeys, clinical pathology analyses
were conducted predose on days 13/11 and 5/7; during dosing on days
42, 78, or 81, 171, and 270 or 273; and during recovery on days 312 or 325 and
442 or 448.
Comprehensive hematology analyses were conducted on tripotassium
ethylenediamine tetra-acetate (K3EDTA)-anticoagulated whole blood using a
CELL-DYN 3500 (Abbott Diagnostics Division, Santa Clara, CA) for cyno-
molgus monkeys and AcT5diff (Beckman Coulter Inc., Miami, FL) for mice for
the following parameters: erythrocyte count, hemoglobin concentration,
hematocrit, total and differential leukocyte counts, mean cell volume, mean
corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and
platelet count. Serum chemistry was analyzed using an AU400 (Olympus
Diagnostic GmbH, Hamburg, Germany) for both species for the following
parameters: glucose, total cholesterol, triglycerides, urea, creatinine, aspartate
aminotransferase, alanine aminotransferase (ALT), alkaline phosphatase, gamma-
glutamyl transferase, total bilirubin, total protein, sodium, potassium, chloride,
calcium, and inorganic phosphorus. Serum protein electrophoresis of monkey sera
was conducted using an SAS-3 electrophoresis analyzer (Helena Biosciences,
Gateshead, UK) to determine albumin, globulin, alpha1-, alpha2-, beta-, and
gamma-globulin fractions. Coagulation parameters were evaluated on sodium
citrate-treated plasma samples collected from cynomolgus monkeys using an ACL
7000 IL coagulometer (Instrumentation Laboratory SpA, Milan, Italy) to determine
the activated partial thromboplastin time and prothrombin time. Urinalysis was
performed on urine collected during a 2-h (mice) or 16-h (cynomolgus monkeys)
post-treatment period. Excreted urine volume was recorded, and urine samples
were analyzed using a Super Aution SA4250 (Menarini Diagnostics, Firenze, Italy)
for the following parameters: specific gravity, color, turbidity, pH, glucose, protein,
bilirubin, urobilinogen, blood, and ketones.
Flow cytometry. Changes in peripheral blood lymphocytes were evaluated
by direct immunofluorescence using flow cytometric immunophenotyping in
both species. K3EDTA-anticoagulated whole blood was incubated in 12 3 75
mm polystyrene round-bottom tubes with Fc Block (1:100 final dilution; BD
Biosciences, San Jose, CA). Samples were mixed and incubated for 15 min at
4C with a working antibody combination (1:40 final dilution of each anti-
body) consisting of CD20/IgD/CD3 for monkeys or B220/IgD/CD5 for
mice (all antibodies were from BD Biosciences except for the anti-human
IgD mAb from Biosource (Carlsbad, CA)). The red blood cells were lysed with
FACS Lysing Solution (BD Biosciences) and fluorescent microspheres
(Flow Count, Beckman Coulter, Fullerton, CA) were added to each sample
tube prior to sample acquisition. Samples were acquired and gated results were
evaluated to determine the absolute concentration of total B cells (CD20þ in
monkeys, B220þ in mice), IgDþ and IgD B cells, and total T cells in
monkey (CD3þ) and mouse (CD5þ) peripheral blood samples. Immunophe-
notyping analysis was conducted on a FACSCalibur flow cytometer using
CellQuest software (BD Biosciences). Determinations were conducted at
various time points before dosing, during dosing, and at the end of the
treatment and recovery periods. For example, flow cytometric analyses were
conducted predose (week 3); during dosing on weeks 7, 13, 21, 24, 29, and
33; and during recovery on weeks 38 and 43 in the chronic toxicity study
conducted in cynomolgus monkeys.
Serum immunoglobulin (IgG, IgM, IgA). Monkey sera were evaluated to
determine total IgA, IgG, and IgM concentration by an immuno-turbidimetric
method (SYNCHRON CX Clinical System, Beckman Coulter). Whereas IgA
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serum concentration was only evaluated in a 39-week monkey toxicity study,
IgG and IgM serum concentrations were evaluated in all safety studies
conducted in monkeys. Total IgG and IgM levels were determined in serum
samples by enzyme-linked immunosorbent assay (ELISA) methods that allow
the relative quantification of IgG or IgM present in test samples using
a commercially available purified mouse IgG or IgM as a standard material
(Jackson ImmunoResearch Europe Ltd, Suffolk, UK, and BD Biosciences).
Microtiter plates were coated with a polyclonal antibody directed against the Fc
portion of the IgG or IgM (Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD) and incubated overnight at approximately 4C. Plates were
blocked with Super Block reagent (Pierce, Rockford, IL). Standards and
samples were added to wells in duplicate and incubated for 1 h at room
temperature while shaken. Horseradish peroxidase (HRP)–conjugated goat anti-
mouse IgG or IgM (Jackson ImmunoResearch Europe, Ltd) were added and
incubated for 1 h at room temperature while shaken. Tetramethylbenzidine
substrate (BioFX Laboratories, Owings Mills, MD) was added and the
subsequent reaction was quantitated at 450 nm with a Victor 1420 reader
(Perkin Elmer, Waltham, MA). Serum Ig concentrations were calculated using
a four-parameter standard curve. Determinations were conducted at various
time points before dosing, during dosing, and at the end of the treatment and
recovery periods. For example, analyses of serum total immunoglobulin were
conducted predose (week 3); during dosing on weeks 7, 13, 21, 24, 29, and
33; and during recovery on weeks 38 and 43 in the chronic toxicity study
conducted in cynomolgus monkeys.
Serum atacicept concentration. Serum atacicept concentrations in both
species were evaluated using a quantitative sandwich ELISA method.
Microtiter plates were coated with a monoclonal antibody specific for atacicept
and incubated overnight at approximately 4C. Plates were blocked with Super
Block reagent (Pierce). Standards and samples were added to wells in duplicate
and incubated (1 h, 37C). Biotinylated anti-atacicept monoclonal antibody was
added and incubated on a shaker plate (1 h, 37C). NeutrAvidine-HRP (Pierce)
and a chemiluminescent substrate (Super Signal Pico, Pierce) were added and
the subsequent signal detected at 425 nm using a Victor 1420 reader (Perkin
Elmer). The standard curve was fitted using quadratic regression (four-parameter
logistic curve). Determinations were conducted at various time points as
described under section ‘‘Pharmacokinetics.’’
Anti-atacicept antibodies. The presence of anti-atacicept binding anti-
bodies in sera was evaluated by an ELISA method in both species. The
method used streptavidin-coated microplates (Thermo Labsystems, Franklin,
MA) and was based on the formation of a sandwich between biotin-atacicept
conjugate, anti-atacicept antibody, and HRP-atacicept conjugate. Results
were expressed as the ratio between optical densities for the postdose sample
and for a blank monkey/mouse serum (considered as nonspecific binding).
Pooled sera spiked with a goat-anti-human TACI polyclonal antibody (R&D
Systems, Minneapolis, MN) were used as positive control samples.
Determinations were conducted at various time points before dosing, during
dosing, and at the end of the treatment and recovery periods. For example,
sera was collected for analysis of anti-atacicept antibodies predose (week 1);
during dosing on weeks 4, 8, 12, 16, 20, 25, 29, and 33; and during recovery on
weeks 38 and 43 during the chronic toxicity study in cynomolgus monkeys.
Anatomic pathology. The animals were euthanized by exsanguination
while under deep anesthesia induced with sodium pentothal. A complete gross
necropsy was performed and included collection of macroscopic observations,
organ weight measurements, and a comprehensive collection of tissue samples
for microscopic examination. Tissues were preserved in neutral buffered 10%
formalin, routinely processed and embedded in paraffin, sectioned, stained with
hematoxylin and eosin, and examined by light microscopy by a board-certified
veterinary pathologist. The eyes of both species and the testes and
epididymides of monkeys were fixed in modified Davidson’s solution and
processed with the other tissues. The testes and epididymides of mice were
fixed for at least 24 h in Bouin’s fixative, transferred to 50% alcohol, and
subsequently processed with the other tissues.
Immunohistochemistry. Immunohistochemical analysis for B and T cells
was performed at the end of dosing (week 4) and recovery (week 8) in the
spleen and mesenteric lymph nodes of mice and in the spleen of cynomolgus
monkeys treated for 4 weeks with vehicle or atacicept. In these studies,
immunohistochemical detection of B cells was conducted using an anti-
CD45R/B220 monoclonal antibody (clone RA3-6B2; BD Biosciences) in mice
and an anti-CD20 monoclonal antibody (clone L26; Dako Italia SpA, Milan,
Italy) in monkeys. Immunohistochemical detection of T cells was conducted
using an anti-CD3 polyclonal antibody (Sigma, St Louis, MO) in mice and an
anti-CD3 monoclonal antibody (clone PC3/188A, Dako Italia SpA) in
monkeys. In the 39-week study in monkeys, bone marrow, spleen, and
mesenteric lymph nodes were evaluated at the end of dosing (week 39) and
recovery (week 54) for B-cells (anti-CD20, L26 clone; Dako), IgA (goat
anti-monkey IgA, a-chain-specific clone; Tebu-bio, Milan, Italy), IgG (goat
anti-monkey IgG, c-chain-specific clone; Tebu-bio) and IgM (goat anti-
monkey IgM, l-chain-specific clone; Tebu-bio). In addition, plasma cells (anti-
CD138, DL-101 clone; Tebu-bio) were evaluated in bone marrow. An
evaluation of optimal antibody titrations was conducted to minimize non-
specific staining.
Following deparaffination and rehydration, the primary antibodies to the
specific targets were applied and incubated. For all procedures, biotin-
conjugated primary or secondary antibodies were subsequently incubated and
stained with streptavidin-HRP. Detection signals were based on the final
conversion of diaminobenzidine as a substrate.
Pharmacokinetics. The PK of atacicept was estimated following a single
intravenous (iv) or sc dose (PK studies) and following repeated sc doses
(toxicokinetic studies) in both mice and monkeys (see Table 1). In PK
studies, samples were collected at 0 (predose), 0.083 (iv only), 0.25, 0.5, 1,
2, 4, 6 (sc only), 8, 16, 24, 72, 120, 168, and 336 h after dose administration.
In toxicokinetic studies, samples were collected in mice at 2, 6, and 48 h
following the first treatment and at similar times on the day of sacrifice as
shown in Table 1. In monkey studies, samples for toxicokinetic evaluation
were collected at the time of the first dose, in weeks 2 and 4 during the
4-week study, and generally in weeks 6, 12, 26, and 39 during the 39-week
study. Once in each of those weeks, blood was drawn predose and at 2-, 6-,
24-, 48-, and 72-h postdose. Atacicept serum levels were determined
according to the above-described method.
Noncompartmental PK parameters were estimated using WinNonLin
software (v. 3.1, Pharsight Corporation, Mountain View, CA). Composite
serum versus time profiles were derived for mice and individual serum versus
time profiles were derived for monkeys. Peak concentration after dosing (Cmax)
and time-to-peak concentration after dosing (Tmax) were the values estimated.
The area under the serum concentration versus time curve (AUC) was
calculated using the log-linear trapezoidal rule (i.e., linear up to the Cmax,
logarithmic after the Cmax). The terminal half-life (t1/2) was calculated by linear
regression of the terminal (log-linear) portion of the concentration versus time
curve. The total clearance (CL) was calculated as dose/AUC and the volume of
distribution at steady state (Vss) was calculated as CL 3 mean residence time.
Absolute sc bioavailability (F) was calculated as the ratio of the sc dose-
normalized AUC to the iv AUC.
Statistical analyses. In the repeated-dose toxicity studies, numerical data
from dosed animals were compared with those from the control group. Group
variances were compared using Bartlett’s test. For data with homogenous
variances across all groups, a one-way ANOVA was performed. If significant
differences (p  0.05) were indicated by the ANOVA, a test for differences
between the control and treatment groups was conducted using Dunnett’s test.
When data had nonhomogeneous variance, a Kruskal-Wallis nonparametric
ANOVA analysis was conducted, and a Mann-Whitney ‘‘U’’ test was
conducted if warranted. In the safety pharmacology studies, analysis of
variance for repeated measurements was performed with a Newman-Keuls test
(p  0.05) versus controls.
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RESULTS
PK of Atacicept in Mice and Monkeys
Single-dose PK. Single-dose atacicept PK were evaluated
in cynomolgus monkeys (using a cross-over study design) and
mice, as summarized in Table 1 (Figs. 1 and 2). In the first
period, three monkeys (group 1) received atacicept as a single
iv dose (1 mg/kg) while three other monkeys (group 2)
received atacicept as a single sc dose (1 mg/kg). After a 2-week
wash-out (period 2), animals in both groups received atacicept
as a single sc dose (group 1, 5 mg/kg; group 2, 15 mg/kg).
In mice, after a single 1 mg/kg iv injection, atacicept was
eliminated from the body with an elimination half-life of 44 h
and the AUCINF was 100 h x lg/ml. A sc injection of 1 mg/kg
atacicept was associated with an AUCINF of 76.6 h x lg/ml,
resulting in an estimated 77% F. Whereas the high sc dose
increased 15-fold relative to the low dose, the AUCINF
increased only eightfold, suggesting a loss of dose proportion-
ality at the high dose; as a result, the estimated bioavailability
(F) decreased to 0.42 at the high dose.
The elimination half-life of atacicept in monkeys was 179 h
and the AUCINF was 215 h 3 lg/ml following a single 1 mg/kg
iv injection. The AUCINF was dose proportional following sc
administration. The bioavailability of sc atacicept was 0.92,
1.02, and 0.81 following 1, 5, and 15 mg/kg doses, respec-
tively. This suggests nearly complete absorption of atacicept
by this route of administration. Low levels of atacicept were
found in the predose samples for all six monkeys from period
2. This was anticipated because the cross-over design of the
study only allowed for two half-lives during the wash-out
period before the second dose administration. However, only
an estimated 2% of the AUCINF from the previous dose in
period 1 overlapped with the AUCINF in period 2.
Overall, atacicept was well absorbed when sc administered,
with bioavailability after a single dose approximately equal to
100% in both species at doses ranging from 1 to 15 mg/kg
(except at 15 mg/kg in mice, where it was lower than
expected). Tmax was 4–16 h in mice and 6–8 h in monkeys,
with t1/2 calculated to be approximately 40–50 h in mice and
140–190 h in monkeys.
Repeat-dose PK and antibody determinations in CD-1
mice. Following a single sc dose of atacicept (0.4, 2, or 10
mg/kg), measures of exposure (Cmax and AUC2–48) increased
in an approximately dose-proportional fashion (Tables 2
and 3). However, there were notable changes in Cmax and
AUC2–48 between the first dose and after 13 or 26 weeks of
dosing. In the 0.4 dose group, exposure was decreased at
week 13 compared with day 1 (Table 2). In the 0.4 mg/kg
dose groups, exposure was increased at week 13 compared
with day 1. After 26 weeks of dosing, exposure was decreased
in both the 0.4 and 2 mg/kg dose groups and increased in the
10 mg/kg dose group compared with day 1. These differential
changes in exposure between the dose levels resulted in a loss
of proportionality in exposure between the dose groups.
The PK of atacicept after repeated administration of higher
doses was evaluated in the 4-week toxicology study only
(Table 3). Following a single sc dose of atacicept (5, 20, or
80 mg/kg), the measures of exposure (Cmax and AUC2–48)
increased in an approximately dose-proportional fashion
(Table 3). After repeated dosing, exposure decreased when
compared with day 1, the decrease being more evident for the
80 mg/kg dose group, resulting in a loss of proportionality at
the highest dose tested.
In the 26-week toxicology study, binding antibodies were
measurable starting at week 4 in approximately half of the mice
at the 0.4 mg/kg dose, and in approximately a quarter of the
mice at the 2 mg/kg dose. No anti-atacicept binding antibodies
were observed in the 10 mg/kg dose group, whereas the
antibody response persisted through 13 weeks of recovery in
the 0.4 and 2 mg/kg dose groups. These results suggest that the
relationship between dose and incidence rate of anti-atacicept
antibody-positive mice was not attributable to interference in
the antibody assay. Antibody responses developed in the dose
groups where decreased exposure was observed, suggesting
that the decrease in mean atacicept exposure could be due to
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FIG. 1. Atacicept PK profile in cynomolgus monkeys after a single dose.
Three monkeys per group were treated with a single iv (1 mg/kg) or sc (1, 5, or
15 mg/kg) injection of atacicept. Data presented as mean serum atacicept
concentration (lg/ml) ± SD.
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FIG. 2. Atacicept PK profile in mice after a single dose. Seventy mice
per group were treated with a single iv (1 mg/kg) or sc (1, 5, or 15 mg/kg)
injection of atacicept. Data presented as mean serum atacicept concentration
(lg/ml) ± SD.
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the presence of anti-atacicept binding antibodies in some
mice. Mice that were positive for anti-atacicept binding
antibodies showed higher IgG and IgM serum levels
compared with concurrently treated mice, which suggested
that development of anti-human atacicept antibodies in this
species interfered with the biological activity of atacicept.
Gender differences in PK were not observed at any dose
tested in mice.
Repeated-dose PK and antibody determinations in
cynomolgus monkeys. Following a single sc dose of 0.4, 2,
or 10 mg/kg atacicept to cynomolgus monkeys, measures of
exposure (Cmax and AUC0–72) increased in an approximately
dose-proportional fashion. As expected, based on the half-life
of atacicept, accumulation was observed with dosing Q3D, and
exposure at week 13 was approximately double that of Day 1
(Table 2). At week 26, a decrease in the mean exposure was
observed at the 0.4 mg/kg dose. However, this reduced
exposure was no longer observed by week 39. In monkeys
that were followed through the recovery period after 13 weeks
(high dose group only) or 26 weeks of dosing, atacicept serum
levels slowly decreased and were quantifiable up to 168–250 h
after the last dose in the low dose group and up to 672 h in the
middle and high dose groups. From week 6/7 onwards, the
atacicept serum levels decreased in some monkeys. This
decrease correlated with the development of an anti-atacicept
antibody detected in one to two monkeys per group. The
incidence rate of antibody-positive monkeys tended to stay the
same or decrease during the recovery, suggesting low drug
interference in the antibody assay.
Similarly to mice, the PK of atacicept after repeated
administration of higher doses in monkeys was evaluated in
the 4-week toxicology study only (Table 3). Following a single
sc dose of atacicept (5, 20, or 80 mg/kg), the AUC0–72
increased in an approximately dose-proportional fashion
whereas the Cmax increased with the dose but not in
a proportional way. Accumulation was expected and observed
after 4 weeks of thrice-weekly dosing, even if at the highest
dose group, 80 mg/kg, the increase was less than expected from
the dose increase, resulting in a loss of proportionality.
TABLE 2
Cmax and AUC in Mice and Monkeys after 26 or 39 Weeks of Repeated Subcutaneous Dosing
Species Week
Cmax (lg/ml) AUCtau
a (h 3 lg/ml)
0.4 mg/kg 2 mg/kg 10 mg/kg 0.4 mg/kg 2 mg/kg 10 mg/kg
Mouse Day 1 0.218 1.88 4.71 7.18 52.3 153
Week 13 0.141 3.32 10.2 2.71 95.8 318
Week 26 0.059 1.51 7.36 2.33 57.2 248
Monkey Day 1 1.06 5.62 32.3 30.8 152 900
Week 6/7 1.10 9.94 35.8 45.2 429 1500
Week 13 1.36 10.8 49.8 60.2 426 1940
Week 26 0.87 9.09 34.6 27.1 365 1550
Week 39 1.12 6.89 39.0 34.4 291 1770
Note. Cmax, peak concentration after dosing; AUC, area under curve.
atau, 48 h in mouse and 72 h in monkey.
TABLE 3
Cmax and AUC in Mice and Monkeys after 4 Weeks of Repeated Subcutaneous Dosing
Species Week
Cmax (lg/ml) AUCtau
a (h 3 lg/ml)
5 mg/kg 20 mg/kg 80 mg/kg 5 mg/kg 20 mg/kg 80 mg/kg
Mouse Day 1 6.71 26.4 155 207 863 3950
Week 2 2.80 14.9 173 89.5 393 4250
Week 4 4.08 17.4 50.7 126 482 1310
Monkey Day 1 29.9 209 1080 957 4210 24200
Week 2 40.1 242 1880 1360 6200 35900
Week 4 55.3 326 931 2340 11,200 28100
Note. Cmax, peak concentration after dosing; AUC, area under curve.
atau, 48 h in mouse and 72 h in monkey.
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Gender differences in PK were not observed at any dose tested
in monkeys.
Safety Pharmacology
A single sc injection of up to 80 mg/kg atacicept caused no
demonstrable effect on respiratory function, cardiovascular
function, or body temperature. In contrast, administration of
a single sc injection of 1 mg/kg carbamylcholine as a positive
control agent in the respiratory safety pharmacology study
induced a bronchoconstrictor effect typical of this agent (Lai
et al., 2004; Okazawa et al., 1999). Whereas a single sc
injection of 5 or 20 mg/kg atacicept had no demonstrable effect
on neurobehavioral endpoints, a trend toward hyperalertness
and concomitantly increased spontaneous locomotor activity
was observed after administration of 80 mg/kg atacicept; this
trend reached statistical significance at 1-h postdosing. Clinical
observations of mice and cynomolgus monkeys following
repeated administration of up to 80 mg/kg atacicept in the
course of general toxicity studies did not reveal alterations in
alertness or behavior, suggesting that this may have been an
incidental finding. Administration of a single intrascapular sc
injection of 10 mg/kg chlorpromazine as a positive control
agent in the neurobehavioral safety pharmacology study was
associated with the expected signs of depressed activity,
neurovegetation, and hypothermia in treated mice (Irwin, 1968;
Laverty and Taylor, 1969; Mattsson et al., 1996). The sc
injection of 20 and 80 mg/kg atacicept in conscious
cynomolgus monkeys did not induce any change in arterial
blood pressure, heart rate or ECG recordings. No adverse
clinical signs were observed during the study at any dose level.
An absence of effect on these cardiology endpoints was
confirmed in repeated-dose general toxicity studies conduced
with up to 80 mg/kg atacicept.
General Safety in Mice and Cynomolgus Monkeys
Single dose toxicity studies in mice and cynomolgus
monkeys. A single iv or sc injection of up to 1200 mg/kg
atacicept in mice did not induce appreciable general or local
abnormalities, and no changes in hematology, serum chemistry,
or gross pathology examinations were found at the end of the
14-day observation period. Similarly, no appreciable general or
local clinical abnormalities were seen in cynomolgus monkeys
after a single sc injection of 240 mg/kg atacicept during the
14-day observation period, including changes in body weight,
food consumption, ophthalmology, electrocardiography, heart
rate, hematology, serum chemistry, or plasma coagulation.
Repeated-dose toxicity studies in mice. Atacicept was well
tolerated in mice when administered Q2D as repeated sc
injections of 5, 20, and 80 mg/kg for 2 or 4 weeks, or 0.4, 2,
and 10 mg/kg for up to 26 weeks. Because similar findings
were observed across shorter- and longer-term studies of
atacicept in mice, results are presented below for mice treated
for 26 weeks.
No untoward clinical signs or remarkable clinical pathology
findings were associated with atacicept administration (see Table
2, Supplement). Observed effects were consistent with the
expected pharmacological activity of atacicept in reducing the
survival of Ig-secreting B cells, including dose-related decreases
in total and mature B-cell concentrations in peripheral blood
(Table 3, Supplement) and decreased total serum Ig (IgG, IgM)
concentrations (Table 4, Supplement) and total protein (Table 2,
Supplement), without apparent effects on peripheral T cell
concentrations. Because of blood volume limitations in mice, it
was not possible to follow the effect of treatment over time in the
same mouse, and relative differences were estimated against
results obtained in a baseline (pretreatment) cohort of mice. At
the end of 26 weeks of treatment with 2 or 10 mg/kg atacicept,
total B cells (B220þ lymphocytes) were approximately 71–82%
lower than baseline (compared with a 28% decrease in vehicle-
treated mice), and IgDþ B cells were approximately 79–87%
lower than baseline (compared with a 32% decrease in vehicle-
treated mice). An associated decrease in total serum IgG (59–
85% decrease) and IgM (> 99% decrease, to below the assay
detection limit) was observed at the end of treatment among
animals dosed with 2 and 10 mg/kg atacicept, respectively,
compared with baseline mice. In contrast, both IgG and IgM
increased, by 466 and 248%, respectively, among vehicle-treated
mice at the end of treatment compared with baseline. Serum Ig
concentrations recovered over the course of the 12-week dose-free
period and were generally similar to results in vehicle-treated
control mice; a similar trend toward recovery in peripheral blood
B-cell populations was apparent over the 12-week dose-free
period, although the total and IgDþ B-cell populations remained
lower than in baseline or vehicle-treated mice. An observed
increase in total lymphocytes among atacicept-treated mice as
assessed by hematology analysis (Table 2, Supplement) is not
explained by observed effects on T or B cells as assessed by flow
cytometry, and may represent an artifact of sampling different
mice for these endpoints. The flow cytometric and serum immu-
noglobulin analyses demonstrate that administration of atacicept
specifically reduces B220þ and IgDþ B cells and concomitantly
reduces IgG and IgM serum levels.
Histopathology analyses demonstrated a dose-related lym-
phocyte reduction in lymph node cortices (data not shown) and
in the marginal zone of the spleen (Fig. 3). Immunohisto-
chemistry confirmed a dose-related reduction of B cells (anti-
CD45R/B220) in the spleen and mesenteric lymph nodes,
whereas no changes in the T cell population (anti-CD3) were
observed (data not shown). A dose-related sc inflammation
with eosinophilia was observed at the injection site in some
mice. Following a postdosing recovery period of 4 weeks in
mice treated with atacicept for up to 4 weeks or 13 weeks in
mice treated for up to 26 weeks, there was nearly complete or
complete resolution of histopathology findings.
Repeated-dose toxicity studies in monkeys. Atacicept was
well tolerated in cynomolgus monkeys when administered
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Q3D as repeated sc injections of 5, 20, and 80 mg/kg for
4 weeks or 0.4, 2, and 10 mg/kg for up to 39 weeks. As with
mice, similar findings were observed across shorter- and
longer-term studies of atacicept in monkeys; thus results are
presented below for monkeys treated for 39 weeks. A slight
elevation in serum ALT concentrations was observed among
two monkeys treated with 10 mg/kg atacicept for 36 weeks,
which was not observed in other treatment groups or at the end
of the recovery period (Table 2, Supplement). No histological
evidence of hepatocellular injury was observed in these
monkeys, and this finding has not been observed in other
studies. In addition to these findings, sc inflammation (mainly
perivascular mononuclear and eosinophilic cell infiltrates) was
observed histologically at the injection site and was considered
to be related to the local presence of the administered
exogenous protein.
Observed effects in monkeys were consistent with the
expected pharmacological activity of atacicept in reducing
survival of Ig-secreting B cells, including dose-related
decreases in total, IgDþ, and IgD B-cell concentrations in
peripheral blood without apparent effects on peripheral T-cell
concentrations (Fig. 4 Table 3, Supplement, except IgD
B cells, which are not shown), decreased total lymphocytes
(Table 2, Supplement), and decreased total serum Ig concen-
trations (IgG, IgM: Fig. 4 and Table 4, Supplement; IgA: data
not shown) and total protein (Table 2, Supplement). At the
end of the 39-week dosing period, total B cells were reduced
by approximately 50% and IgDþ B cells were reduced
by approximately 60% among monkeys treated with 2 and
FIG. 3. Photomicrographs of the normal mouse spleen (A), and
cynomolgus monkey spleen (B) and lymph node (C) stained with hematoxylin
and eosin. Lymphocyte depletion was observed in the splenic follicular
marginal zone after treatment with atacicept in mice (A#) and cynomolgus
monkeys (B#), and in the corona (mantle) of the germinal centers of the lymph
node of cynomolgus monkeys (C#). In these studies, 10 mg/kg atacicept was
administered via sc injection to mice (three times weekly, 26 weeks) or
cynomolgus monkeys (twice weekly, 39 weeks).
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FIG. 4. Mean percentage change over time in baseline mature B cells
(IgDþ/CD20þ) and serum IgG and serum IgM concentrations in cynomolgus
monkeys treated twice weekly with vehicle or atacicept (0.4, 2, 10 mg/kg) via
sc injection for 39 weeks (n ¼ 10) followed by a 25-week dose-free period
(n ¼ 4). Summary flow cytometric and serum Ig concentrations in mice and
cynomolgus monkeys over time are provided in Tables 4 and 5.
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10 mg/kg atacicept when compared with their own predose
baseline samples. The decrease in peripheral B cells was
associated with decreases in total serum IgG (39–49%) and
IgM concentrations (> 99%, to below the assay detection limit)
in monkeys at the end of treatment compared with their own
predose baseline samples (Fig. 4 and Table 4, Supplement).
Histopathology findings were limited to reversible lymphocyte
reduction in the follicular marginal zone of the spleen and the
corona (mantle) surrounding germinal centers of the lymph
nodes (Fig. 3). Immunohistochemical analysis demonstrated
reduced B cells (CD20) at all doses in the spleen but not
mesenteric lymph nodes or bone marrow, with no detectable
effect on plasma cells (CD138) or T cells (CD3) in these organs
(data not shown). In addition, decreases in cells expressing IgG
in the spleen (Fig. 5) and bone marrow (data not shown), IgA
in the bone marrow (data not shown), and IgM in the spleen
(Fig. 5) and mesenteric lymph nodes (data not shown) were
observed after 39 weeks of dosing.
The atacicept-related effects on the immune system, in-
cluding reduced B cells in peripheral blood and lymphoid
tissues and reduced serum Ig concentrations (Fig. 4 and Tables
3 and 4, Supplement), were reversible with termination of
treatment, and peripheral B-cell and serum total Ig concen-
trations were generally similar to (or higher than) baseline
levels by the end of the 25-week dose-free period. We
concluded from this data that administration of atacicept in
both mice and monkeys reduced the number of B cells in
peripheral blood and lymphoid tissues as well as circulating
IgM and IgG concentrations. Given that dose-responsive
changes in peripheral and tissue B cells and total immuno-
globulin concentrations were consistent with the expected
pharmacological activity of this molecule and that there were
no untoward adverse effects attributable to atacicept under the
conditions tested, a no adverse effect level was established at
the highest tested dose (i.e., 80 mg/kg in 4-week studies and
10 mg/kg in chronic studies) in both mice and cynomolgus
monkeys.
DISCUSSION
We describe in this report the preclinical safety and
pharmacology of atacicept. Atacicept was well tolerated in
both mice and cynomolgus monkeys over a broad dose range
and for extensive periods of time without obvious organ
toxicity without evidence of infection. Administration of
atacicept reduced B cells and IgM and IgG serum levels consis-
tent with the expected pharmacological activity of atacicept.
The lack of treatment-related findings indicating infections
further corroborate our previous observation that atacicept does
not impact on host resistance to influenza virus infection
(Roque et al., 2006). In this model, no effect on viral clearance
or survival was observed following atacicept treatment, despite
reduction in influenza-specific Ig production and peripheral
B-cell populations. Similarly, pretreatment of mice with atacicept
did not alter clearance of a subsequent bacterial infection
(Streptococcus pneumoniae, Type 14; Heffernan et al., 2008).
These data collectively suggest that sufficient compensatory
capacity to clear opportunistic infection persists in atacicept-
treated animals. A mechanistic explanation could be that BLyS
and APRIL are not required for mouse memory B-cell survival
and function (Benson et al., 2008). This could be extrapolated
to patients. Interestingly, SLE patients treated with atacicept
had protective anti-tetanus antibody post-treatment levels
(Dall’Era et al., 2007). This preliminary data suggest that after
BLyS and APRIL blockade, a patient’s memory B-cell
compartment might persist and be poised to protect against
previously encountered pathogens.
In both species, the immunological effects of atacicept
administration were consistent with suppression of Ig-secreting
B cells, without notable effects on other white blood cells,
including T cells. Observed effects included reduced mature
B cells in peripheral blood and lymphoid tissues, reduced serum
Ig concentrations, and a decrease in Ig-producing cells in
lymphoid tissues. These effects of atacicept support a specific
activity of BLyS and APRIL in supporting B cell proliferation,
differentiation, and survival as previously described (Dillon et al.,
2006; Mackay et al., 2007). In addition, the immunomodulatory
effect of atacicept was reversible, as evidenced by recovery of
mature B cells and Ig concentrations within 2–3 months of
treatment cessation in both mice and cynomolgus monkeys.
Atacicept demonstrated low immunogenicity, especially in
monkeys. In mice, the presence of binding antibodies was
associated with a reduction of the biological activity of
atacicept on IgG and IgM serum levels. In monkeys the
FIG. 5. Photomicrographs (310) of the normal cynomolgus monkey
spleen stained with hematoxylin and eosin and either anti-IgG (A) or anti-IgM
(B). Depletion of Ig-positive lymphocytes was observed in the spleen after
treatment with atacicept in cynomolgus monkeys, as identified by anti-IgG (A#)
or anti-IgM (B#) immunohistochemistry. Atacicept (10 mg/kg) was adminis-
tered twice weekly via sc injection to cynomolgus monkeys for 39 weeks.
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presence of binding antibodies was associated with decreased
serum levels of atacicept. Observation of a decreased incidence
of animals developing anti-drug antibodies with greater
atacicept dose is likely the result of the ability of atacicept to
suppress antibody responses and could be predicted for an
agent that mediates B-cell inhibition; given the timing of the
blood draws during the recovery period it is unlikely that the
low antibody response could be attributed to assay interference
by circulating atacicept.
The effects of atacicept in cynomolgus monkeys share some
basic PD properties observed with other BLyS antagonists,
including BR3-Fc (Vugmeyster et al., 2006) and belimumab
(Halpern et al., 2006). BR3-Fc is a recombinant protein
containing the extracellular domain of the human BR3
(BAFF-R) fused with a human IgG Fc domain. Belimumab is
a recombinant fully human IgG1 monoclonal antibody targeting
BLyS. Both of these molecules neutralize BLyS, but not APRIL.
Similarly to atacicept, BR3-Fc and belimumab were well
tolerated in safety studies conducted in nonhuman primates.
Treatment with either agent was associated with reversible
decreases in CD20þ B cells in peripheral blood and lymphoid
tissues, without notable effects on T cells or leukocytes as
assessed by flow cytometry, immunohistochemistry, and
hematology analysis. In addition, both BR3-Fc and atacicept
reduce marginal zone B cells in spleen and lymph nodes.
Atacicept treatment reduced serum IgG concentrations to
approximately 50% of baseline and could deplete IgM to
undetectable levels in both mice and monkeys. In contrast, total
serum Ig levels were not markedly affected by belimumab
(Halpern et al., 2006), and the effects of BR3-Fc on total serum
Ig concentrations were not reported, although a mild, statisti-
cally significant decrease in the IgG response to repeated
tetanus immunization was observed (Vugmeyster et al., 2006).
Because atacicept targets both BLyS and APRIL, whereas
BR3-Fc and belimumab target only BLyS, these data suggest
a possible role for APRIL and/or the combination of BLyS and
APRIL in the maintenance of serum Ig concentrations. Indeed,
several recent studies in mice have demonstrated that BLyS
inhibition alone with BAFFR-Ig treatment does not significantly
inhibit the survival of normal or malignant (multiple myeloma)
plasma cells, whereas inhibition of both BLyS and APRIL with
atacicept significantly reduces Ig-secreting plasma cells without
affecting memory B cells (Benson et al., 2008; Ramanujam
et al., 2006; Yaccoby et al., 2008). Comparison of results from
clinical trials of BLyS-only inhibitors, such as belimumab and
BR3-Fc, to those from atacicept trials will ultimately determine
whether neutralizing APRIL and BLyS together has greater
therapeutic benefit than neutralizing BLyS alone.
In conclusion, atacicept was well tolerated in mice and
cynomolgus monkeys, with findings limited to local inflam-
mation at the site of atacicept administration and specific
decreases in B lymphocytes and immunoglobulins in tissues
and in peripheral blood, which recovered in a treatment-free
follow-up period. These nonclinical studies, which evaluated
administered dose levels 3- to 90-fold higher (on a body weight
basis) than doses administered in Phase 1 clinical studies,
supported the safe administration of atacicept in healthy
volunteers and patients with SLE, rheumatoid arthritis, or
B-cell malignancies (Ansell et al., 2008; Dall’Era et al., 2007;
Munafo et al., 2007; Tak et al., 2008).
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.
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TABLE 1 (Supplemental) 
Pharmacokinetic Parameters in Mice and Monkeys, Single Dose 
Species Route Dose 
(mg/kg)
Tmax 
(h) 
Cmax 
(µg/ml)
AUC 
(h*µg/ml) 
t1/2 
(h) 
CL 
(ml/h/kg) 
Vz 
(ml/kg)
Vss 
(ml/kg)
F 
 
Mouse iv 1 – – 100 44 9.99 638 169 – 
 sc 1 16 2.09 76.6 45 – – – 0.76 
 sc 5 8 16.9 444 53 – – – 0.89 
 sc 15 4 18.1 631 37 – – – 0.42 
Monkey iv 1 - - 215 179 4.30 1090 382 - 
 sc 1 6 5.14 185 192 – – – 0.92 
 sc 5 6 32.4 1140 137 – – – 1.02 
 sc 15 8 87.2 2750 153 – – – 0.81 
AUC, area under curve; CL, total clearance; Cmax, peak concentration after dosing; F, bioavailability; t1/2, terminal half life; 
Tmax, time to peak concentration; Vss, volume of distribution at steady state; Vz terminal exponential volume of 
distribution. 
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Table 2 (Supplement):  Selected clinical pathology data (mean ± SE (n)) from cynomolgus monkeys and CD-1 mice at the end of the 
dosing and recovery periods1 
Cynomolgus monkeys Mouse 
Atacicept Atacicept 
 
0 mg/kg 10 mg/kg 0 mg/kg 10 mg/kg 
Total Protein (g/dL)2 End of Dosing 7.3 ± 0.08 (9) 6.6 ± 0.13 (10) 5.3 ± 0.06 (20) 5.0 ± 0.08 (20) 
 End of Recovery 7.3 ± 0.17 (4) 6.9 ± 0.12 (4) 5.5 ± 0.06 (19) 5.4 ± 0.07 (20) 
Glucose (mg/dL) 2 End of Dosing 89.7 ± 5.03 (9) 70.2 ± 3.97 (10) 171.1 ± 8.54 (20) 149.7 ± 10.55 (20) 
 End of Recovery 63.0 ± 3.24 (4) 64.3 ± 5.95 (4) 152.5 ± 8.05 (19) 133.6 ± 10.55 (20) 
ALT (U/L) 2 End of Dosing 55.7 ± 4.62 (9) 131.0 ± 47.38 (10) 35.5 ± 3.52 (20) 43.0 ± 3.84 (20) 
 End of Recovery 37.8 ± 8.75 (4) 66.3 ± 12.31 (4) 32.9 ± 2.21 (18) 32.0 ± 2.72 (20) 
Cholesterol (mg/dL) 2 End of Dosing 137.7 ± 6.38 (9) 133.8 ± 9.26 (10) 102.6  ± 5.43 (20) 95.3 ± 6.88 (20) 
 End of Recovery 121.8 ± 14.94 (4) 129.25 ± 14.84 (4) 114.6 ± 8.61 (17) 85.4 ± 9.67 (17) 
Triglycerides (mg/dL) 2 End of Dosing 45.0 ± 5.01 (9) 47.2 ± 2.75 (10) 86.9 ± 7.00 (20) 75.6 ± 7.93 (20) 
 End of Recovery 44.3 ± 3.69 (4) 43.8 ± 6.07 (4) 84.8 ± 8.98 (17) 56.3 ± 8.20 (17) 
Bilirubin (mg/dL) 2 End of Dosing 0.26 ± 0.02 (9) 0.23 ± 0.02 (10) 0.17 ± 0.01 (20) 0.21 ± 0.05 (20) 
 End of Recovery 0.21 ± 0.03 (4) 0.22 ± 0.04 (4) 0.26  ± 0.04 (17) 0.25 ± 0.02 (17) 
Creatinine (mg/dL) 2 End of Dosing 0.88 ± 0.03 (9) 0.84 ± 0.03 (10) 0.39 ± 0.01 (20) 0.35 ± 0.01 (20) 
 End of Recovery 0.91± 0.06 0.91± 0.05 (4) 0.36 ± 0.01 (19) 0.35 ± 0.01 (20) 
Calcium (mg/dL) 2 End of Dosing 8.69 ± 0.39 (9) 8.68 ± 0.34 (10) 7.63 ± 0.05 (20) 7.71 ± 0.06 (20) 
 End of Recovery 10.08 ± 0.13 (4) 9.55 ± 0.11 (4) 6.55 ± 0.07 (17) 5.31 ± 0.47 (20) 
Erythrocytes (x106/μL) 3 End of Dosing 5.34 ± 0.15 (9) 5.59 ± 0.11 (10) 8.64± 0.17 (20) 8.70 ± 0.21 (20) 
 End of Recovery 5.32 ± 0.16 (4) 5.52 ± 0.08 (4) 8.28 ± 0.14 (19) 8.18 ± 0.27 (20) 
Lymphocytes (x103/μL) 3 End of Dosing 7.77 ± 0.79 (9) 5.69 ± 0.43 (10) 0.62 ± 0.07 (20) 1.07 ± 0.36 (20) 
 End of Recovery 7.09 ± 0.67 (4) 5.29 ± 0.40 (4) 0.80 ± 0.10 (19) 1.20 ± 0.33 (20) 
Neutrophils (x103/μL) 3 End of Dosing 2.91 ± 0.43 (9) 3.35 ± 0.59 (10) 0.08 ± 0.01 (20) 0.11 ± 0.02 (20) 
 End of Recovery 3.14 ± 0.77 (4) 3.13 ± 0.28 (4) 0.09 ± 0.02 (19) 0.09 ± 0.01 (20) 
Platelets (x103/μL) 3 End of Dosing 353.3 ± 18.16 (9) 382.9 ± 27.88 (10) 698.8 ± 25.0 (20) 704.2 ± 38.1 (20) 
 End of Recovery 338.8 ± 38.99 (4) 358.5 ± 44.71 (4) 760.3 ± 28.1 (19) 716.4 ± 53.9 (20) 
1 End of dosing measurements occurred during Week 27 for CD-1 mice and Week 36 for cynomolgus monkeys.  End of recovery measurements occurred during Week 40 for CD-
1 mice and Week 64 for cynomolgus monkeys.  2 Clinical chemistry measurements obtained using sera as described in Materials and Methods.  3 Hematology measurements 
obtained using EDTA-treated whole blood as described in Materials and Methods. 
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TABLE 3 (Supplemental) 
Flow Cytometric Immunophenotyping of Peripheral Blood Lymphocytes of Cynomolgus Monkeys and  
CD-1 Mice Prior to Dosing (Baseline), at the End of Dosing, and at the End of the Recovery Period 
  Total B cells (cells/μl)a Mature B cells (cells/μl)b T cells (cells/μl)c 
Cynomolgus monkeys Baseline Week 38 Week 64 Baseline Week 38 Week 64 Baseline Week 38 Week 64 
Vehicle GeoMean  
(95% CI mean), n 
793  
(533, 1179) 
10 
903 
(689, 1183) 
10 
1105 
(390, 3133) 
4 
347 
(208, 580) 
10 
417 
(306, 570) 
10 
653 
(240, 1781) 
4 
3700 
(2692, 5086) 
10 
4120 
(3595, 4722) 
10 
5504 
(4166, 7271) 
4 
 Baseline difference (%) – 13.9 89.6** – 20.1 116.1* – 11.3 39.4 
Atacicept 
0.4 mg/kg 
GeoMean  
(95% CI mean), n 
854 
(645, 1132) 
10 
742 
(492, 1119) 
10 
1843 
(889, 3821) 
4 
249 
(27, 2261) 
10 
277 
(48, 1589) 
10 
706 
(45, 10970) 
4 
3920 
(1862, 8256) 
10 
4977 
(2609, 9494) 
10 
5504 
(3154, 9606) 
4 
 Baseline difference (%) – -13.2 87.4* – 11.4 189.7* – 26.9* 39.4 
Atacicept 
2 mg/kg 
GeoMean  
(95% CI mean), n 
858 
(685, 1075) 
10 
397 
(281, 562) 
10 
636 
(273, 1478) 
4 
347 
(262, 461) 
10 
137 
(92, 203) 
10 
264 
(81, 865) 
4 
4086 
(2948, 5663) 
10 
4349 
(2990, 6326) 
10 
3919 
(872, 17617) 
4 
 Baseline difference (%) – -53.7*** -12.7 – -60.7*** -7.3 – 6.4 -7.3 
Atacicept 
10 mg/kg 
GeoMean  
(95% CI mean), n 
766 
(562, 1043) 
10 
385 
(265, 560) 
10 
1204 
(809, 1790) 
4 
319 
(209, 486) 
10 
132 
(81, 213) 
10 
763 
(472, 1235) 
4 
3698 
(2906, 4705) 
10 
3730 
(2812, 4948) 
10 
4462 
(2805, 7098) 
4 
 Baseline difference (%) – -49.8** 54.1 – -58.7** 152.6* – 0.9 40.4* 
 
CD-1 mice Baseline Week 27 Week 38 Baseline Week 27 Week 38 Baseline Week 27 Week 38 
Vehicle GeoMean  
(95% CI mean), n 
276 
(206, 371) 
20 
198 
(110, 357) 
8 
180 
(104, 314) 
8 
274 
(207, 364) 
20 
186 
(100, 346) 
8 
170 
(96, 302) 
8 
576 
(482, 687) 
20 
277 
(187, 411) 
8 
279 
(212, 368) 
8 
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 Baseline difference (%) – -28.4 -34.7 – -32.1 -37.9 – -51.9** -51.5*** 
Atacicept 
0.4 mg/kg 
GeoMean  
(95% CI mean), n 
– 205 
(21, 1983) 
8 
324 
(16, 6386) 
7 
– 181 
(13, 2517) 
8 
282 
(14, 5601) 
7 
– 438 
(189, 1061) 
8 
407 
(114, 1455) 
7 
 Baseline difference (%) – -25.6 17.4 – -34.1 3.0 – -24.0 -29.3 
Atacicept 
2 mg/kg 
GeoMean  
(95% CI mean), n 
– 81 
(34, 189) 
8 
176 
(55, 569) 
6 
– 59 
(21, 162) 
8 
150 
(52, 436) 
6 
– 431 
(238, 781) 
8 
357 
(221, 578) 
6 
 Baseline difference (%) – -70.8** -36.2 – -78.5*** -45.2 – -25.1 -37.9 
Atacicept 
10 mg/kg 
GeoMean  
(95% CI mean), n 
– 50 
(25, 99) 
8 
126 
(51, 313) 
8 
– 35 
(15, 82) 
8 
120 
(54, 270) 
8 
– 546 
(315, 948) 
8 
252 
(157, 406) 
8 
 Baseline difference (%) – -81.8*** -54.2 – -87.2*** -56.1 – -5.1 -56.2*** 
GeoMean: geometric mean; 95% CI mean: 95% confidence interval around the mean; n: number of animals per group. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
aTotal B cells defined within a lymphocyte (forward versus side-scatter) gate as B220+ cells for mice and CD20+ cells for cynomolgus monkeys. 
bMature B cells defined within a lymphocyte (forward versus side-scatter) gate as IgD+/B220+ cells for mice and IgD+/CD20+ cells for cynomolgus monkeys. 
cTotal T cells defined within a lymphocyte (forward versus side-scatter) gate as CD5+ cells for mice and CD3+ cells for cynomolgus monkeys.
TABLE 4 (Supplemental) 
Serum Total IgG and IgM Concentration in Cynomolgus Monkeys and CD-1 Mice Prior to  
Dosing (Baseline), at the End of Dosing, and at the End of the Recovery Period 
  IgG (mg/dl) IgM (mg/dl) 
Cynomolgus monkeys Baseline Week 39 Week 64 Baseline Week 39 Week 64 
Vehicle GeoMean  
(95% CI mean), n 
1040 
(942, 1150) 
10 
933 
(868, 1004) 
10 
1059 
(784, 1431) 
4 
69 
(49, 97) 
10 
58 
(45, 74) 
10 
46 
(22, 97) 
4 
 Baseline difference (%) – -10.3** 3.6 – -16.6 -27.6 
Atacicept 
0.4 mg/kg 
GeoMean  
(95% CI mean), n 
1018 
(919, 1127) 10 
827 
(733, 934) 
10 
1005 
(886, 1141) 
4 
84 
(62, 114) 
10 
20 
(3, 134) 
10 
65 
(40, 104) 
4 
 Baseline difference (%) – -18.7*** -3.5 – -76.7 -16* 
Atacicept 
2 mg/kg 
GeoMean  
(95% CI mean), n 
1107 
(976, 1257) 
10 
673 
(555, 816) 
10 
1143 
(740, 1763) 
4 
62 
(53, 72) 
10 
0 
(0, 1) 
10 
48 
(26, 87) 
4 
 Baseline difference (%) – -39.3*** -2.9 – -99.9*** -22.5 
Atacicept 
10 mg/kg 
GeoMean  
(95% CI mean), n 
937 
(878, 1000) 
10 
474 
(361, 623) 
10 
898 
(713, 1131) 
4 
79 
(59, 105) 
10 
0 
(0, 5) 
10 
69 
(34, 139) 
4 
 Baseline difference (%) – -49.4*** -2.3 – -99.7** -6.5 
       
CD-1 mice Baseline Week 27 Week 38 Baseline Week 27 Week 38 
Vehicle GeoMean  
(95% CI mean), n 
35.7 
(28.8, 44.2) 
20 
202.3 
(145.5, 281.4) 
8 
144.1  
(98.2, 211.4) 
8 
1.5 
(0.77, 3.4) 
20 
5.2 
(2.9, 9.5) 
8 
6.9 
(4.5, 10.4) 
8 
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 Baseline difference (%) – 466.28*** 303.31*** – 248.03 356.99* 
Atacicept 
0.4 mg/kg 
GeoMean  
(95% CI mean), n 
– 97.6 
(45.3, 210.2) 
8 
11.5 
(71.6, 184.4) 
8 
– 1.1 
(0.1, 12.6) 
8 
4.7 
(1.9, 11.8) 
8 
 Baseline difference (%) – 173.27** 221.61*** – -27.24 213.71 
Atacicept 
2 mg/kg 
GeoMean  
(95% CI mean), n 
– 14.7 
(5.8, 37.0) 
8 
83.3 
(40.1, 173.2) 
8 
– 0 
(0, 0) 
8 
2.6 
(1.9, 3.6) 
8 
 Baseline difference (%) – -58.9* 133.27** – -100*** 73.48 
Atacicept 
10 mg/kg 
GeoMean  
(95% CI mean), n 
– 5.3 
(2.8, 10.4) 
8 
39.0 
(22.6, 67.1) 
8 
– 0 
(0, 0) 
8 
2.8 
(1.9, 4.0) 
8 
 Baseline difference (%) – -85.05*** 9.05 – -100*** 83.5 
GeoMean: geometric mean; 95% CI mean: 95% confidence interval around the mean; n: number of animals per group. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
